Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Profit drops and CEO moves at Ranbaxy

January 23, 2006 | A version of this story appeared in Volume 84, Issue 4

Ranbaxy Laboratories has reported a 2005 net profit of $58 million, a 62% drop from a year ago. Sales reached $1.17 billion. The company blames the drop, its second consecutive annual profit decline, on weak pricing in the key U.S. market. Ranbaxy also announced that its CEO, Brian W. Tempest, has been replaced by Malvinder Mohan Singh, who had headed the company's pharmaceutical business. In a move billed as a promotion, Tempest is now chief mentor and executive vice chairman of Ranbaxy's board. Singh is the eldest son of Ranbaxy's late founder, Parvinder Singh.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.